Cargando…
Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients
BACKGROUND: Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases, resulting in a dismal prognosis. The present study aimed to determine the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM. METHODS: The stu...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184451/ https://www.ncbi.nlm.nih.gov/pubmed/34164509 http://dx.doi.org/10.21037/atm-21-2550 |
_version_ | 1783704592137060352 |
---|---|
author | Wang, Nan Liu, Fangqi Xi, Wenqi Jiang, Jinling Xu, Yun Guan, Bingjie Wu, Junwei Zhou, Chenfei Shi, Min Zhu, Zhenggang Xu, Ye Liu, Jing Zhang, Jun |
author_facet | Wang, Nan Liu, Fangqi Xi, Wenqi Jiang, Jinling Xu, Yun Guan, Bingjie Wu, Junwei Zhou, Chenfei Shi, Min Zhu, Zhenggang Xu, Ye Liu, Jing Zhang, Jun |
author_sort | Wang, Nan |
collection | PubMed |
description | BACKGROUND: Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases, resulting in a dismal prognosis. The present study aimed to determine the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM. METHODS: The study was based on a training cohort of 214 mCRC patients (of which, 101 patients had BM) from our center, and a validation cohort of 511 mCRC patients (of which, 173 patients had BM) from another institute. Risk and prognostic nomograms for BM were developed using univariate and multivariate analyses. The goodness of fit, discrimination, and calibration performance of the nomograms were assessed by R(2), concordance statistics (C-statistics), and the calibration curve. The results were internally validated using bootstrap resampling in the training cohort, and externally validated in the validation cohort. RESULTS: The novel BM risk nomogram comprised seven variables [degree of tumor differentiation, N-stage, serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), liver metastasis, and lung metastasis]. It showed good performance, with an R(2) of 0.447 and a C-statistic of 0.846 [95% confidence interval (CI), 0.793 to 0.898] in the training cohort, and an R(2) of 0.325 and a C-statistic of 0.792 (95% CI, 0.750 to 0.834) in the validation cohort. The optimal cutoff value to identify individuals at low or high risk was 56% probability, with a sensitivity of 71.3% and a specificity of 89.4%. The prognostic nomogram included five factors (tumor differentiation, number of extra-BM organs, number of BM lesions, ALP, and LDH), and had an R(2) of 0.284 and a C-statistic of 0.723 (95% CI, 0.657 to 0.789) in the training set. This nomogram was externally validated in the validation cohort, with an R(2) of 0.182 and a C-statistic of 0.682 (95% CI, 0.638 to 0.726). CONCLUSIONS: The developed and validated risk and prognostic nomograms showed good performance for predicting the occurrence of BM in mCRC as well as the prognosis of CRC patients with BM. The risk nomogram can be used as a cost-effective preliminary screening tool prior to bone scanning. |
format | Online Article Text |
id | pubmed-8184451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | AME Publishing Company |
record_format | MEDLINE/PubMed |
spelling | pubmed-81844512021-06-22 Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients Wang, Nan Liu, Fangqi Xi, Wenqi Jiang, Jinling Xu, Yun Guan, Bingjie Wu, Junwei Zhou, Chenfei Shi, Min Zhu, Zhenggang Xu, Ye Liu, Jing Zhang, Jun Ann Transl Med Original Article BACKGROUND: Bone metastases (BM) from colorectal cancer (CRC) are often accompanied by extraosseous metastases, resulting in a dismal prognosis. The present study aimed to determine the risk factors for BM in metastatic CRC (mCRC) and the prognostic factors for CRC patients with BM. METHODS: The study was based on a training cohort of 214 mCRC patients (of which, 101 patients had BM) from our center, and a validation cohort of 511 mCRC patients (of which, 173 patients had BM) from another institute. Risk and prognostic nomograms for BM were developed using univariate and multivariate analyses. The goodness of fit, discrimination, and calibration performance of the nomograms were assessed by R(2), concordance statistics (C-statistics), and the calibration curve. The results were internally validated using bootstrap resampling in the training cohort, and externally validated in the validation cohort. RESULTS: The novel BM risk nomogram comprised seven variables [degree of tumor differentiation, N-stage, serum alkaline phosphatase (ALP), lactate dehydrogenase (LDH), carcinoembryonic antigen (CEA), liver metastasis, and lung metastasis]. It showed good performance, with an R(2) of 0.447 and a C-statistic of 0.846 [95% confidence interval (CI), 0.793 to 0.898] in the training cohort, and an R(2) of 0.325 and a C-statistic of 0.792 (95% CI, 0.750 to 0.834) in the validation cohort. The optimal cutoff value to identify individuals at low or high risk was 56% probability, with a sensitivity of 71.3% and a specificity of 89.4%. The prognostic nomogram included five factors (tumor differentiation, number of extra-BM organs, number of BM lesions, ALP, and LDH), and had an R(2) of 0.284 and a C-statistic of 0.723 (95% CI, 0.657 to 0.789) in the training set. This nomogram was externally validated in the validation cohort, with an R(2) of 0.182 and a C-statistic of 0.682 (95% CI, 0.638 to 0.726). CONCLUSIONS: The developed and validated risk and prognostic nomograms showed good performance for predicting the occurrence of BM in mCRC as well as the prognosis of CRC patients with BM. The risk nomogram can be used as a cost-effective preliminary screening tool prior to bone scanning. AME Publishing Company 2021-05 /pmc/articles/PMC8184451/ /pubmed/34164509 http://dx.doi.org/10.21037/atm-21-2550 Text en 2021 Annals of Translational Medicine. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) . |
spellingShingle | Original Article Wang, Nan Liu, Fangqi Xi, Wenqi Jiang, Jinling Xu, Yun Guan, Bingjie Wu, Junwei Zhou, Chenfei Shi, Min Zhu, Zhenggang Xu, Ye Liu, Jing Zhang, Jun Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients |
title | Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients |
title_full | Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients |
title_fullStr | Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients |
title_full_unstemmed | Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients |
title_short | Development and validation of risk and prognostic nomograms for bone metastases in Chinese advanced colorectal cancer patients |
title_sort | development and validation of risk and prognostic nomograms for bone metastases in chinese advanced colorectal cancer patients |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184451/ https://www.ncbi.nlm.nih.gov/pubmed/34164509 http://dx.doi.org/10.21037/atm-21-2550 |
work_keys_str_mv | AT wangnan developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT liufangqi developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT xiwenqi developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT jiangjinling developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT xuyun developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT guanbingjie developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT wujunwei developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT zhouchenfei developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT shimin developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT zhuzhenggang developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT xuye developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT liujing developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients AT zhangjun developmentandvalidationofriskandprognosticnomogramsforbonemetastasesinchineseadvancedcolorectalcancerpatients |